ALPHA HEALTHCARE(US:ALPA)2025-08-14 20:31Company Overview - Longevity Health Holdings, Inc. is focused on longevity and healthy aging, offering cosmetic skincare and haircare products primarily in the United States through business-to-business, direct-to-consumer, and distributor sales channels [125]. Mergers and Acquisitions - The THPlasma Merger is set to merge Longevity with True Health, with Longevity acquiring True Health's rights and licenses from the U.S. Food and Drug Administration [126][127]. - The Merger Consideration includes 19,666,667 shares of Common Stock and 6,666,667 shares of Parent Common Stock, contingent on performance metrics being met post-merger [128]. - The License Purchase for $5 million will occur concurrently with the Merger Closing, contingent on the sale of equity or debt securities of at least $5 million [130]. - The Elevai Acquisition involved the purchase of assets from PMGC Holdings Inc. for 38,308 shares of Common Stock and additional cash payments based on future sales performance [137][138]. - The termination of the Biolabs Merger Agreement occurred on July 8, 2025, with no termination fees owed by either party [133][134]. Financial Performance - Gross sales for Q2 2025 reached $535,978, a significant increase of 4,114% compared to $12,720 in Q2 2024, primarily driven by products from the Elevai Acquisition [154]. - Net sales for the first half of 2025 were $1,013,965, up 8,130% from $12,320 in the same period of 2024 [161]. - The company reported a net loss of $3,392,305 for the six months ended June 30, 2025, which is a 51% improvement compared to a net loss of $6,857,700 in the same period of 2024 [161]. - Operating expenses for Q2 2025 totaled $2,161,262, an increase of 80% from $1,203,515 in Q2 2024 [154]. - Gross sales for the six months ended June 30, 2025, were $1,070,921, a significant increase from $12,720 in the same period of 2024, primarily driven by the Elevai Acquisition [162]. - Net revenue for the first half of 2025 was $1,013,965, compared to $12,320 for the same period in 2024, reflecting a substantial growth [162]. Expenses and Cash Flow - Research and development expenses rose to $228,606 in Q2 2025, a 120% increase from $104,066 in Q2 2024, largely due to the Elevai Acquisition [158]. - Selling and marketing expenses rose to $626,054 for the six months ended June 30, 2025, up from $11,045 in 2024, due to increased marketing efforts related to the Elevai Acquisition [163]. - Research and development expenses decreased by $107,968 to $425,518 for the first half of 2025 compared to 2024, mainly due to workforce reductions in non-core areas [164]. - General and administrative expenses increased to $2,840,128 for the six months ended June 30, 2025, from $1,992,268 in 2024, driven by higher professional fees [165]. - Net cash used in operating activities improved to $(1,589,143) in the first half of 2025, a 28% decrease from $(2,214,254) in 2024 [172]. - Net cash provided by financing activities increased to $3,148,203 for the six months ended June 30, 2025, compared to $2,248,864 in 2024, reflecting successful capital raises [175]. Stock and Capital Structure - A reverse stock split at a ratio of 1:30 was executed on May 12, 2025, affecting the number of shares and their respective exercise prices [135]. - The company received gross proceeds of approximately $1.85 million from a Common Stock offering on January 2, 2025, and $1.96 million from ATM Financing in May 2025 [152]. - The fair value of the Placement Agent Warrant at issuance was approximately $0.31 million, with an exercise price of $6.90 [140]. - Following a Reverse Stock Split, the exercise price of the Common Stock Warrants was adjusted to $3.36, increasing the total shares issuable to 552,798 [141]. Liquidity and Financial Concerns - The company had negative net working capital of $3,672,761 as of June 30, 2025, indicating financial strain [150]. - As of June 30, 2025, the company had cash of $1,551,199 and negative working capital of $3,672,761, raising concerns about liquidity for the next 12 months [167]. - The company is exploring out-licensing of certain R&D programs to enhance liquidity while significantly reducing operating expenses [153]. Future Outlook - The company is currently focused on the successful completion of the THPlasma Merger and the associated benefits while managing ongoing business operations [124]. - The Elevai Acquisition contributed approximately $2.5 million in revenue in 2024, and management anticipates further revenue growth from ongoing commercialization of cosmetic products [168].